Zusammenfassung
Opioid-Antagonisten weisen eine Affinität zu Opioidre-zeptoren auf. Per definitionem induzieren sie (in klinischer Dosierung) keine intrinsischen opioidergen Wirkungen. Opioid-Antagonisten besetzen reversibel, kom-petitiv und aufgrund des Massenwirkungsgesetzes Opioidrezeptoren und verdrängen dort reversibel gebundene Opioide bzw. opioiderge Liganden.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Literatur bis1996: s. CD-ROM
Foss JF, O’Connor MF, Yuan CS et al. (1997) Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study. J Clin Pharmacol 37/1: 25–30
Foss JF, Yuan CS, Roizen MF et al. (1998) Prevention of apomor-phine- or cisplatin-induced emesis in the dog by a combination of methylnaltrexone and morphine. Cancer Chemother Pharmacol 42/4: 287–291
Shen KF, Crain SM (1997) Ultra-low doses of naltrexone or etor-phine increase morphine’s antinociceptive potency and attenuate tolerance/dependence in mice.Brain Res 757/2: 176–190
Yuan CS, Foss JF, Osinski J et al. (1997) The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin Pharmacol Ther 61/4: 467–475
Yuan CS, Foss JF, O’Connor M et al. (1999) Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy : a pilot study. Pain 83: 631–635
Literatur bis1996:s. CD-ROM
Bergasa NV, Ailing DW, Talbot TL et al. (1999) Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 41 (3 Pt 1): 431–434
Bergasa NV, Schmitt JM, Talbot TL et al. (1998) Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 3: 679–684
Frye RF, Matzke GR, Schade R et al. (1997) Effects of liver disease on the disposition of the opioid antagonist nalmefene. Clin Pharmacol Ther 61/1: 15–23
Kaplan JL, Marx JA, Calabro JJ et al. (1999) Double-blind, randomized study of nalmefene and naloxone in emergency department patients with suspected narcotic overdose. Ann Emerg Med 34/1: 42–50
Wang DS, Sternbach G, Varon J (1998) Nalmefene: a long-acting opioid antagonist. Clinical applications in emergency medicine. J Emerg Med 3: 471–475
Literatur bis1996:s. CD-ROM
Meissner W, Schmidt U, Hartmann M et al. (2000) Oral naloxone reverses opioid-associated constipation. Pain 84: 105–109
Literatur bis1996:s. CD-ROM
King AC, Volpicelli JR, Gunduz M et al. (1997) Naltrexone biotransformation and incidence of subjective side effects: a preliminary study. Alcohol Clin Exp Res 5: 906–909
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Waldvogel, H.H. (2001). Opioide: Antagonisten. In: Analgetika Antinozizeptiva Adjuvanzien. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56710-0_43
Download citation
DOI: https://doi.org/10.1007/978-3-642-56710-0_43
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-63005-7
Online ISBN: 978-3-642-56710-0
eBook Packages: Springer Book Archive